- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03206177
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
September 27, 2021 updated by: University of Oklahoma
Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
The objective of the study is to determine whether this drug combination is safe for this patient population and to see if it is effective in shrinking cancers, keeping them from growing or helping patients live longer.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients who consent to this study will receive treatment for four 28 day cycles unless they are unable to continue study treatment due to toxicity or disease progression.
Paclitaxel and carboplatin will be given intravenously on day 1 of each cycle and galunisertib in pill form on days 4-17.
No medicine will be given on days 17-28 of each cycle.
Patients may have the option of continuing treatment with the study drug if they complete the 4 cycles the study requires.
Subjects will receive tests and procedures that are part of regular cancer care as well as those required for the purposes of the study.
Blood samples will be taken to monitor the level of study drug in the blood.
Patients will have the option of allowing blood and tumor samples to be used for future research.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 97 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women ≥ 18 years old with a diagnosis of primary, recurrent or progressive uterine, ovarian, fallopian tube or peritoneal carcinosarcoma, for whom treatment with combination paclitaxel and carboplatin is recommended.
- Written informed consent/assent prior to any study-specific procedures
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Tissue available for translational study (paraffin block or new biopsy) .
- Adequate bone marrow, renal, and hepatic function as defined per protocol.
- No disease-modifying therapy, including investigational treatments, within 28 days prior to initiation of study treatment.
- Ability to swallow tablets
- For Women of child-bearing potential:Willingness to use a highly effective method of contraception during the study and for 6 months following the last dose of galunisertib. Negative beta human chorionic gonadotropin pregnancy test documented within 7 days prior to initiation of study drug.
- Patient must have measurable disease before the treatment
Exclusion Criteria:
- Planned radiotherapy during or after the study chemotherapy prior to disease progression.
- Receipt of chemotherapy or radiation within 28 days of study treatment
- Have had a major surgical procedure or a significant traumatic injury within 28 days prior to study treatment; Minor procedures such as biopsy within 7 days prior to study treatment are allowed.
- Active infection that would preclude receipt of chemotherapy
- Moderate or severe cardiovascular disease per protocol
- Active pregnancy or lactation
- Second primary malignancy for which treatment during the study period would be recommended if this cancer were not also present.
- Prior malignancy requiring treatment within the last 3 years
- Use of another investigational product or device within 4 weeks of study entry or during study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paclitaxel/Carboplatin + Galunisertib
|
Galunisertib 150mg po BID day 4-17.)
Paclitaxel 175 mg/m2 over 3 hours
IV day 1 Carboplatin AUC 6* over 1 hour (or 5* if no prior radiation therapy)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with completion of 4 cycles of CT + GB
Time Frame: 2 years
|
To determine the feasibility of delivering 4 cycles of carboplatin/paclitaxel (CT) in combination with galunisertib (GB) to patients with gynecologic carcinosarcoma
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of adverse events
Time Frame: 2 years
|
To determine the frequency and severity of adverse events as assessed by the CTCAE v4
|
2 years
|
Median progression free survival (months)
Time Frame: through study completion, an average of 3 years
|
To determine the PFS of patients receiving drug combination
|
through study completion, an average of 3 years
|
Mean (SD) of GB serum concentration levels on day 4, 8 and 29 (cycle 2 day 1)
Time Frame: 2 months
|
Galunisertib serum concentration levels will be tested
|
2 months
|
Median overall survival (months)
Time Frame: through study completion, an average of 3 years
|
To determine the overall survival of patients receiving drug combination
|
through study completion, an average of 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 20, 2017
Primary Completion (Actual)
July 28, 2021
Study Completion (Anticipated)
August 19, 2023
Study Registration Dates
First Submitted
June 1, 2017
First Submitted That Met QC Criteria
June 29, 2017
First Posted (Actual)
July 2, 2017
Study Record Updates
Last Update Posted (Actual)
October 4, 2021
Last Update Submitted That Met QC Criteria
September 27, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Complex and Mixed
- Sarcoma
- Carcinosarcoma
- Mixed Tumor, Mullerian
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
Other Study ID Numbers
- OU-SCC-EXIST-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinosarcoma, Ovarian
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedCarcinosarcoma, Ovarian | Carcinosarcomas UterineItaly
-
Sun Yat-sen UniversityHutchmedRecruitingOvarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma | Fallopian Tube CarcinosarcomaChina
-
University of OklahomaGenentech, Inc.CompletedPrimary Peritoneal Carcinoma | Ovarian Carcinosarcoma | Advanced Ovarian CarcinomaUnited States
-
ARCAGY/ GINECO GROUPTesaro, Inc.Active, not recruitingOvarian Carcinosarcoma | Endometrial CarcinosarcomaFrance
-
National Cancer Institute (NCI)CompletedFallopian Tube Cancer | Uterine Carcinosarcoma | Stage IV Ovarian Epithelial Cancer | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Carcinosarcoma | Female Reproductive... and other conditionsUnited States, Canada
-
Mayo ClinicRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditionsUnited States
-
Australia New Zealand Gynaecological Oncology GroupMerck Sharp & Dohme LLC; Eisai Inc.RecruitingUterine Carcinosarcoma | Ovarian CarcinosarcomaCanada, Australia, United Kingdom
-
University of WashingtonNational Cancer Institute (NCI)TerminatedOvarian Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Ovarian... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedNeutropenia | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Infectious DisorderUnited States
-
University of Alabama at BirminghamWithdrawnCarcinosarcoma of Ovary | Carcinosarcoma of Uterus | Carcinosarcoma of VaginaUnited States
Clinical Trials on Galunisertib
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedMyelodysplastic SyndromesGermany, Spain, Italy
-
Abramson Cancer Center of the University of PennsylvaniaCompletedADVANCED HEPATOCELLULAR CARCINOMA (HCC)United States
-
Eli Lilly and CompanyAstraZenecaCompletedMetastatic Pancreatic CancerSpain, United States, Korea, Republic of, France, Italy
-
The Netherlands Cancer InstituteEli Lilly and Company; Universitaire Ziekenhuizen KU Leuven; European Organisation... and other collaboratorsWithdrawnGalunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)Colorectal Cancer MetastaticNetherlands
-
The Netherlands Cancer InstituteAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Not yet recruitingColorectal Cancer Metastatic | Peritoneal CarcinomatosisNetherlands
-
Stony Brook UniversityFDA Office of Orphan Products Development; State University of New YorkCompletedSepsis | Respiratory Distress Syndrome | Respiratory Distress Syndrome, AdultUnited States
-
Eli Lilly and CompanyBristol-Myers SquibbCompletedSolid Tumor | Hepatocellular Carcinoma Recurrent | Non-Small Cell Lung Cancer RecurrentSpain, United States
-
Eli Lilly and CompanyCompletedNeoplasms | Neoplasm Metastasis | Pancreatic CancerUnited States, Germany, Spain, Belgium, Italy, France